Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy

Heterogeneous immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy

The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive condit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiotherapy and oncology 2022-01, Vol.166, p.88-91
Hauptverfasser: Bowes, Cynthia L., Naranbhai, Vivek, St. Denis, Kerri J., Lam, Evan C., Bertaux, Brittany, Keane, Florence K., Khandekar, Melin J., Balazs, Alejandro B., Iafrate, John A., Gainor, Justin F., Willers, Henning
Format: Artikel
Sprache:eng
Schlagworte:
BNT162 Vaccine
COVID-19
COVID-19 Vaccines
Humans
Immunogenicity
Lung cancer
mRNA vaccine
Neoplasms - radiotherapy
Prospective Studies
Radiotherapy
SARS-CoV-2
Short Communication
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The immunogenicity of SARS-CoV-2 vaccines in cancer patients receiving radiotherapy is unknown. This prospective cohort study demonstrates that anti-SARS-CoV-2 spike antibody and neutralization titers are reduced in a subset of thoracic radiotherapy patients, possibly due to immunosuppressive conditions. Antibody testing may be useful to identify candidates for additional vaccine doses.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2021.11.012